hrs-1358
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 30, 2022 (NCT05628870)
Timeline
Indications
Studied for
Mechanism of action
- Estrogen receptorDEGRADER
Estrogen receptor degrader
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07125950 | Phase 2 | Sep 30, 2025 | Henan Medical University |
| NCT06679036 | Phase 1/Phase 2 (Phase 2) | Nov 25, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06555068 | Phase 1/Phase 2 (Phase 2) | Aug 12, 2024 | Hengrui Therapeutics, Inc. |
| NCT05628870 | Phase 1 | Dec 30, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 2 | 2 | 2 | 2022 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1